Skip to main content
NCBI home page
Transactions of the American Ophthalmological Society logoLink to Transactions of the American Ophthalmological Society
. 1998;96:721–752.

Tumor vascularity and hematogenous metastasis in experimental murine intraocular melanoma.

H E Grossniklaus 1
PMCID: PMC1298413  PMID: 10360307

Abstract

PURPOSE: The purpose of this study is to test the hypothesis that primary tumor vascularity in a murine model of intraocular melanoma positively correlates with the development and hematogenous spread of metastasis. METHODS: Forty 12-week-old C57BL6 mice were inoculated in either the anterior chamber (AC) or posterior compartment (PC) of 1 eye with 5 x 10(5) cells/microL of Queens tissue culture melanoma cells. The inoculated eye was enucleated at 2 weeks; the mice were sacrificed at 4 weeks postinoculation, and necropsies were performed. The enucleated eyes were examined for histologic and ultrastructural features, including relationship of tumor cells to tumor vascular channels, vascular pattern, and mean vascular density. RESULTS: Melanoma grew and was confined to the eye in 12 of 20 AC eyes and 10 of 20 PC eyes. Histologic and electron microscopic examination showed tumor invasion into vascular channels. Five of 12 AC tumors (42%) and 8 of 10 PC tumors (80%) metastasized. All of the AC tumors, but none of the PC tumors, that distantly metastasized also metastasized to ipsilateral cervical lymph nodes (P = .00535). There was no statistically significant difference of vascular pattern between the melanomas that did and did not metastasize to lungs in the PC group (P = .24), although there was a significant difference in the AC group (P = .02). Tumors with high-grade vascular patterns were more likely to metastasize than tumors with low-grade vascular patterns in the AC group. The mean vascular density positively correlated with the presence and number of metastases in both groups (P = .0000 and P < .001, respectively). There was no statistically significant difference of vascular pattern and mean vascular density for AC versus PC melanoma (P = .97). CONCLUSIONS: The rate of metastasis in this murine intraocular melanoma model positively correlates with primary tumor vascularity. The melanoma metastasizes via invasion of tumor vascular channels. AC melanoma also metastasizes through regional lymphatics.

Full text

PDF
721

Images in this article

732FIGURE 3
on p.732
732FIGURE 4
on p.732
734FIGURE 5
on p.734
734FIGURE 6
on p.734
735FIGURE 7
on p.735
735FIGURE 8
on p.735
736FIGURE 9
on p.736
736FIGURE 10
on p.736
737FIGURE 11
on p.737
737FIGURE 12
on p.737
738FIGURE 13
on p.738
740FIGURE 14
on p.740
740FIGURE 15
on p.740
745FIGURE 16
on p.745

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anand R., Ma D., Alizadeh H., Comerford S. A., Sambrook J. F., Gething M. J., McLean I. W., Niederkorn J. Y. Characterization of intraocular tumors arising in transgenic mice. Invest Ophthalmol Vis Sci. 1994 Aug;35(9):3533–3539. [PubMed] [Google Scholar]
  2. Bradl M., Klein-Szanto A., Porter S., Mintz B. Malignant melanoma in transgenic mice. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):164–168. doi: 10.1073/pnas.88.1.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brooks P. C., Montgomery A. M., Rosenfeld M., Reisfeld R. A., Hu T., Klier G., Cheresh D. A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994 Dec 30;79(7):1157–1164. doi: 10.1016/0092-8674(94)90007-8. [DOI] [PubMed] [Google Scholar]
  4. Brown D., Boniuk M., Font R. L. Diffuse malignant melanoma of iris with metastases. Surv Ophthalmol. 1990 Mar-Apr;34(5):357–364. doi: 10.1016/0039-6257(90)90111-8. [DOI] [PubMed] [Google Scholar]
  5. Char D. H., Castro J. R., Quivey J. M., Chen G. T., Lyman J. T., Stone R. D., Irvine A. R., Barricks M., Crawford J. B., Hilton G. F. Helium ion charged particle therapy for choroidal melanoma. Ophthalmology. 1980 Jun;87(6):565–570. doi: 10.1016/s0161-6420(80)35195-6. [DOI] [PubMed] [Google Scholar]
  6. Char D. H., Crawford J. B., Irvine A. R., Hogan M. J., Howes E. L., Jr Correlation between degree of malignancy and the radioactive phosphorus uptake test in ocular melanomas. Am J Ophthalmol. 1976 Jan;81(1):71–75. doi: 10.1016/0002-9394(76)90193-8. [DOI] [PubMed] [Google Scholar]
  7. Char D. H. History of ocular oncology. Ophthalmology. 1996 Aug;103(8 Suppl):S96–101. doi: 10.1016/s0161-6420(96)30767-7. [DOI] [PubMed] [Google Scholar]
  8. Claffey K. P., Brown L. F., del Aguila L. F., Tognazzi K., Yeo K. T., Manseau E. J., Dvorak H. F. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 1996 Jan 1;56(1):172–181. [PubMed] [Google Scholar]
  9. Contrino J., Hair G. A., Schmeizl M. A., Rickles F. R., Kreutzer D. L. In situ characterization of antigenic and functional tissue factor expression in human tumors utilizing monoclonal antibodies and recombinant factor VIIa as probes. Am J Pathol. 1994 Dec;145(6):1315–1322. [PMC free article] [PubMed] [Google Scholar]
  10. DUNN T. B. Normal and pathologic anatomy of the reticular tissue in laboratory mice, with a classification and discussion of neoplasms. J Natl Cancer Inst. 1954 Jun;14(6):1281–1433. [PubMed] [Google Scholar]
  11. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  12. FLOCKS M., GERENDE J. H., ZIMMERMAN L. E. The size and shape of malignant melanomas of the choroid and ciliary body in relation to prognosis and histologic characteristics; a statistical study of 210 tumors. Trans Am Acad Ophthalmol Otolaryngol. 1955 Nov-Dec;59(6):740–758. [PubMed] [Google Scholar]
  13. Fidler I. J., Gersten D. M., Budmen M. B. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res. 1976 Sep;36(9 PT1):3160–3165. [PubMed] [Google Scholar]
  14. Fidler I. J. Selection of successive tumour lines for metastasis. Nat New Biol. 1973 Apr 4;242(118):148–149. doi: 10.1038/newbio242148a0. [DOI] [PubMed] [Google Scholar]
  15. Fine S. L. No one knows the preferred management for choroidal melanoma. Am J Ophthalmol. 1996 Jul;122(1):106–108. doi: 10.1016/s0002-9394(14)71970-1. [DOI] [PubMed] [Google Scholar]
  16. Folberg R., Mehaffey M., Gardner L. M., Meyer M., Rummelt V., Pe'er J. The microcirculation of choroidal and ciliary body melanomas. Eye (Lond) 1997;11(Pt 2):227–238. doi: 10.1038/eye.1997.57. [DOI] [PubMed] [Google Scholar]
  17. Folberg R., Pe'er J., Gruman L. M., Woolson R. F., Jeng G., Montague P. R., Moninger T. O., Yi H., Moore K. C. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol. 1992 Nov;23(11):1298–1305. doi: 10.1016/0046-8177(92)90299-i. [DOI] [PubMed] [Google Scholar]
  18. Folberg R., Rummelt V., Parys-Van Ginderdeuren R., Hwang T., Woolson R. F., Pe'er J., Gruman L. M. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993 Sep;100(9):1389–1398. doi: 10.1016/s0161-6420(93)31470-3. [DOI] [PubMed] [Google Scholar]
  19. Folkman J. Angiogenesis and breast cancer. J Clin Oncol. 1994 Mar;12(3):441–443. doi: 10.1200/JCO.1994.12.3.441. [DOI] [PubMed] [Google Scholar]
  20. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995 Jan;1(1):27–31. doi: 10.1038/nm0195-27. [DOI] [PubMed] [Google Scholar]
  21. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995 Jan;1(1):27–31. doi: 10.1038/nm0195-27. [DOI] [PubMed] [Google Scholar]
  22. Folkman J. The vascularization of tumors. Sci Am. 1976 May;234(5):58-64, 70-3. doi: 10.1038/scientificamerican0576-58. [DOI] [PubMed] [Google Scholar]
  23. Foss A. J., Alexander R. A., Jefferies L. W., Hungerford J. L., Harris A. L., Lightman S. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996 Jul 1;56(13):2900–2903. [PubMed] [Google Scholar]
  24. Gamel J. W., Gleason J., Williams H., Greenberg R. Reproducibility of nucleolar measurements in human intraocular melanoma cells on standard histologic microslides. Anal Quant Cytol Histol. 1985 Sep;7(3):174–177. [PubMed] [Google Scholar]
  25. Gamel J. W., McCurdy J. B., McLean I. W. A comparison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sci. 1992 May;33(6):1919–1922. [PubMed] [Google Scholar]
  26. Gamel J. W., McLean I. W. Computerized histopathologic assessment of malignant potential. II. A practical method for predicting survival following enucleation for uveal melanoma. Cancer. 1983 Sep 15;52(6):1032–1038. doi: 10.1002/1097-0142(19830915)52:6<1032::aid-cncr2820520618>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  27. Gamel J. W., McLean I. W. Computerized histopathologic assessment of malignant potential. III. Refinements of measurement and data analysis. Anal Quant Cytol. 1984 Mar;6(1):37–44. [PubMed] [Google Scholar]
  28. Gamel J. W., McLean I. W., Greenberg R. A., Zimmerman L. E., Lichtenstein S. J. Computerized histologic assessment of malignant potential: a method for determining the prognosis of uveal melanomas. Hum Pathol. 1982 Oct;13(10):893–897. doi: 10.1016/s0046-8177(82)80048-8. [DOI] [PubMed] [Google Scholar]
  29. Gamel J. W., McLean I. W., McCurdy J. B. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer. 1993 Apr 1;71(7):2299–2305. doi: 10.1002/1097-0142(19930401)71:7<2299::aid-cncr2820710721>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  30. Gamel J. W., McLean I. W. Modern developments in histopathologic assessment of uveal melanomas. Ophthalmology. 1984 Jun;91(6):679–684. doi: 10.1016/s0161-6420(84)34244-0. [DOI] [PubMed] [Google Scholar]
  31. Gamel J. W., McLean I. W. Quantitative analysis of the Callender classification of uveal melanoma cells. Arch Ophthalmol. 1977 Apr;95(4):686–691. doi: 10.1001/archopht.1977.04450040152024. [DOI] [PubMed] [Google Scholar]
  32. Gragoudas E. S., Goitein M., Verhey L., Munzenreider J., Suit H. D., Koehler A. Proton beam irradiation. An alternative to enucleation for intraocular melanomas. Ophthalmology. 1980 Jun;87(6):571–581. doi: 10.1016/s0161-6420(80)35212-3. [DOI] [PubMed] [Google Scholar]
  33. Grossniklaus H. E., Barron B. C., Wilson M. W. Murine model of anterior and posterior ocular melanoma. Curr Eye Res. 1995 May;14(5):399–404. doi: 10.3109/02713689508999938. [DOI] [PubMed] [Google Scholar]
  34. Grossniklaus H. E., Oakman J. H., Cohen C., Calhoun F. P., Jr, DeRose P. B., Drews-Botsch C. Histopathology, morphometry, and nuclear DNA content of iris melanocytic lesions. Invest Ophthalmol Vis Sci. 1995 Mar;36(3):745–750. [PubMed] [Google Scholar]
  35. Grossniklaus H. E., Wilson M. W., Barron B. C., Lynn M. J. Anterior vs posterior intraocular melanoma. Metastatic differences in a murine model. Arch Ophthalmol. 1996 Sep;114(9):1116–1120. doi: 10.1001/archopht.1996.01100140318011. [DOI] [PubMed] [Google Scholar]
  36. Hendrix M. J., Seftor E. A., Seftor R. E., Kirschmann D. A., Gardner L. M., Boldt H. C., Meyer M., Pe'er J., Folberg R. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Pathol. 1998 Apr;152(4):855–863. [PMC free article] [PubMed] [Google Scholar]
  37. Hu L. K., Huh K., Gragoudas E. S., Young L. H. Establishment of pigmented choroidal melanomas in a rabbit model. Retina. 1994;14(3):264–269. doi: 10.1097/00006982-199414030-00014. [DOI] [PubMed] [Google Scholar]
  38. Jakobiec F. A., Silbert G. Are most iris "melanomas' really nevi? A clinicopathologic study of 189 lesions. Arch Ophthalmol. 1981 Dec;99(12):2117–2132. doi: 10.1001/archopht.1981.03930020993002. [DOI] [PubMed] [Google Scholar]
  39. Jiang L. Q., Jorquera M., Streilein J. W. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest Ophthalmol Vis Sci. 1993 Nov;34(12):3347–3354. [PubMed] [Google Scholar]
  40. Journée-de Korver J. G., Oosterhuis J. A., Kakebeeke-Kemme H. M., de Wolff-Rouendaal D. Transpupillary thermotherapy (TTT) by infrared irradiation of choroidal melanoma. Doc Ophthalmol. 1992;82(3):185–191. doi: 10.1007/BF00160764. [DOI] [PubMed] [Google Scholar]
  41. Journée-de Korver J. G., Oosterhuis J. A., van Best J. A., Fakkel J. Xenon arch photocoagulator used for transpupillary hyperthermia. Doc Ophthalmol. 1991;78(3-4):183–187. doi: 10.1007/BF00165679. [DOI] [PubMed] [Google Scholar]
  42. Knisely T. L., Niederkorn J. Y. Immunologic evaluation of spontaneous regression of an intraocular murine melanoma. Invest Ophthalmol Vis Sci. 1990 Feb;31(2):247–257. [PubMed] [Google Scholar]
  43. Kvanta A., Steen B., Seregard S. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res. 1996 Nov;63(5):511–518. doi: 10.1006/exer.1996.0141. [DOI] [PubMed] [Google Scholar]
  44. Lambrou F. H., Chilbert M., Mieler W. F., Williams G. A., Olsen K. A new technique for subchoroidal implantation of experimental malignant melanoma. Invest Ophthalmol Vis Sci. 1988 Jun;29(6):995–998. [PubMed] [Google Scholar]
  45. Liu B., Earl H. M., Baban D., Shoaibi M., Fabra A., Kerr D. J., Seymour L. W. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun. 1995 Dec 26;217(3):721–727. doi: 10.1006/bbrc.1995.2832. [DOI] [PubMed] [Google Scholar]
  46. Lommatzsch P. K. Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years' experience. Br J Ophthalmol. 1986 Nov;70(11):844–851. doi: 10.1136/bjo.70.11.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. MEYER-SCHWICKERATH G. The preservation of vision by treatment of intraocular tumors with light coagulation. Arch Ophthalmol. 1961 Oct;66:458–466. doi: 10.1001/archopht.1961.00960010460004. [DOI] [PubMed] [Google Scholar]
  48. Ma D., Alizadeh H., Comerford S. A., Gething M. J., Sambrook J. F., Anand R., Niederkorn J. Y. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes. Curr Eye Res. 1994 May;13(5):361–369. doi: 10.3109/02713689409167300. [DOI] [PubMed] [Google Scholar]
  49. Ma D., Luyten G. P., Luider T. M., Jager M. J., Niederkorn J. Y. Association between NM23-H1 gene expression and metastasis of human uveal melanoma in an animal model. Invest Ophthalmol Vis Sci. 1996 Oct;37(11):2293–2301. [PubMed] [Google Scholar]
  50. Ma D., Luyten G. P., Luider T. M., Niederkorn J. Y. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci. 1995 Feb;36(2):435–441. [PubMed] [Google Scholar]
  51. Ma D., Niederkorn J. Y. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice. Invest Ophthalmol Vis Sci. 1995 May;36(6):1067–1075. [PubMed] [Google Scholar]
  52. McCurdy J., Gamel J., McLean I. A simple, efficient, and reproducible method for estimating the malignant potential of uveal melanoma from routine H & E slides. Pathol Res Pract. 1991 Dec;187(8):1025–1027. doi: 10.1016/S0344-0338(11)81076-9. [DOI] [PubMed] [Google Scholar]
  53. McLean I. W., Zimmerman L. E., Evans R. M. Reappraisal of Callender's spindle a type of malignant melanoma of choroid and ciliary body. Am J Ophthalmol. 1978 Oct;86(4):557–564. doi: 10.1016/0002-9394(78)90307-0. [DOI] [PubMed] [Google Scholar]
  54. McLean M. J., Foster W. D., Zimmerman L. E. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol. 1977 Jan;95(1):48–58. doi: 10.1001/archopht.1977.04450010050004. [DOI] [PubMed] [Google Scholar]
  55. Mehaffey M. G., Folberg R., Meyer M., Bentler S. E., Hwang T., Woolson R., Moore K. C. Relative importance of quantifying area and vascular patterns in uveal melanomas. Am J Ophthalmol. 1997 Jun;123(6):798–809. doi: 10.1016/s0002-9394(14)71129-8. [DOI] [PubMed] [Google Scholar]
  56. Meissauer A., Kramer M. D., Hofmann M., Erkell L. J., Jacob E., Schirrmacher V., Brunner G. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. Exp Cell Res. 1991 Feb;192(2):453–459. doi: 10.1016/0014-4827(91)90064-2. [DOI] [PubMed] [Google Scholar]
  57. Miller J. W., Adamis A. P., Shima D. T., D'Amore P. A., Moulton R. S., O'Reilly M. S., Folkman J., Dvorak H. F., Brown L. F., Berse B. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994 Sep;145(3):574–584. [PMC free article] [PubMed] [Google Scholar]
  58. Muthukkaruppan V. R., Kubai L., Auerbach R. Tumor-induced neovascularization in the mouse eye. J Natl Cancer Inst. 1982 Sep;69(3):699–708. [PubMed] [Google Scholar]
  59. Niederkorn J. Y. Enucleation in consort with immunologic impairment promotes metastasis of intraocular melanomas in mice. Invest Ophthalmol Vis Sci. 1984 Sep;25(9):1080–1086. [PubMed] [Google Scholar]
  60. Niederkorn J. Y., Knisely T. L., Mayhew E. Immune rejection of metastases arising from intraocular tumors in mice. Invest Ophthalmol Vis Sci. 1986 Sep;27(9):1355–1361. [PubMed] [Google Scholar]
  61. Niederkorn J. Y., Sanborn G. E., Gamel J. W. Suicide enzyme inhibition as a chemotherapeutic strategy for controlling metastases derived from intraocular melanomas. Invest Ophthalmol Vis Sci. 1987 Nov;28(11):1844–1850. [PubMed] [Google Scholar]
  62. Niederkorn J. Y. Suppressed cellular immunity in mice harboring intraocular melanomas. Invest Ophthalmol Vis Sci. 1984 Apr;25(4):447–454. [PubMed] [Google Scholar]
  63. Niederkorn J. Y. T cell subsets involved in the rejection of metastases arising from intraocular melanomas in mice. Invest Ophthalmol Vis Sci. 1987 Aug;28(8):1397–1403. [PubMed] [Google Scholar]
  64. Nuijs-Beems E. M., Oosterhuis J. A., Verburg-van der Marel E. H., de Wolff-Rouendaal D., van Delft J. L., van Best J. A. Tumor destruction by intermediate level hyperthermia. Curr Eye Res. 1990 Aug;9(8):771–780. doi: 10.3109/02713689008999572. [DOI] [PubMed] [Google Scholar]
  65. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994 Oct 21;79(2):315–328. doi: 10.1016/0092-8674(94)90200-3. [DOI] [PubMed] [Google Scholar]
  66. Oosterhuis J. A., Journée-de Korver H. G., Kakebeeke-Kemme H. M., Bleeker J. C. Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol. 1995 Mar;113(3):315–321. doi: 10.1001/archopht.1995.01100030071024. [DOI] [PubMed] [Google Scholar]
  67. Park S. S., Li L., Korn T. S., Mitra M. M., Niederkorn J. Y. Effect of transforming growth factor-beta on plasminogen activator production of cultured human uveal melanoma cells. Curr Eye Res. 1996 Jul;15(7):755–763. doi: 10.3109/02713689609003459. [DOI] [PubMed] [Google Scholar]
  68. Pe'er J., Rummelt V., Mawn L., Hwang T., Woolson R. F., Folberg R. Mean of the ten largest nucleoli, microcirculation architecture, and prognosis of ciliochoroidal melanomas. Ophthalmology. 1994 Jul;101(7):1227–1235. doi: 10.1016/s0161-6420(94)31184-5. [DOI] [PubMed] [Google Scholar]
  69. Powell M. B., Hyman P., Bell O. D., Balmain A., Brown K., Alberts D., Bowden G. T. Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. Mol Carcinog. 1995 Feb;12(2):82–90. doi: 10.1002/mc.2940120205. [DOI] [PubMed] [Google Scholar]
  70. RONES B., ZIMMERMAN L. E. The prognosis of primary tumors of the iris treated by iridectomy. AMA Arch Ophthalmol. 1958 Aug;60(2):193–205. doi: 10.1001/archopht.1958.00940080207003. [DOI] [PubMed] [Google Scholar]
  71. Richerson J. T., Burns R. P., Misfeldt M. L. Association of uveal melanocyte destruction in melanoma-bearing swine with large granular lymphocyte cells. Invest Ophthalmol Vis Sci. 1989 Dec;30(12):2455–2460. [PubMed] [Google Scholar]
  72. Risau W. Angiogenesis and endothelial cell function. Arzneimittelforschung. 1994 Mar;44(3A):416–417. [PubMed] [Google Scholar]
  73. Sanborn G. E., Nguyen P., Gamel J., Niederkorn J. Y., Ngyuen P. Reduction of enucleation-induced metastasis in intraocular melanoma by periorbital irradiation. Arch Ophthalmol. 1987 Sep;105(9):1260–1264. doi: 10.1001/archopht.1987.01060090118040. [DOI] [PubMed] [Google Scholar]
  74. Senger D. R., Van de Water L., Brown L. F., Nagy J. A., Yeo K. T., Yeo T. K., Berse B., Jackman R. W., Dvorak A. M., Dvorak H. F. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993 Sep;12(3-4):303–324. doi: 10.1007/BF00665960. [DOI] [PubMed] [Google Scholar]
  75. Shields C. L., Shields J. A., DePotter P., Kheterpal S. Transpupillary thermotherapy in the management of choroidal melanoma. Ophthalmology. 1996 Oct;103(10):1642–1650. doi: 10.1016/s0161-6420(96)30451-x. [DOI] [PubMed] [Google Scholar]
  76. Shields C. L., Shields J. A., Kiratli H., De Potter P., Cater J. R. Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology. 1995 Sep;102(9):1351–1361. [PubMed] [Google Scholar]
  77. Shields J. A., Augsburger J. J., Brady L. W., Day J. L. Cobalt plaque therapy of posterior uveal melanomas. Ophthalmology. 1982 Oct;89(10):1201–1207. doi: 10.1016/s0161-6420(82)34658-8. [DOI] [PubMed] [Google Scholar]
  78. Shields J. A., Glazer L. C., Mieler W. F., Shields C. L., Gottlieb M. S. Comparison of xenon arc and argon laser photocoagulation in the treatment of choroidal melanomas. Am J Ophthalmol. 1990 Jun 15;109(6):647–655. doi: 10.1016/s0002-9394(14)72432-8. [DOI] [PubMed] [Google Scholar]
  79. Shields J. A., Shields C. L., Donoso L. A. Management of posterior uveal melanoma. Surv Ophthalmol. 1991 Nov-Dec;36(3):161–195. doi: 10.1016/0039-6257(91)90001-v. [DOI] [PubMed] [Google Scholar]
  80. Specht C. S., McLean I. W., Biscoe B. W. Traumatic enucleation for posterior uveal melanoma. Am J Ophthalmol. 1990 Nov 15;110(5):518–521. doi: 10.1016/s0002-9394(14)77875-4. [DOI] [PubMed] [Google Scholar]
  81. Sunba M. S., Rahi A. H., Morgan G. Tumors of the anterior uvea. I. Metastasizing malignant melanoma of the iris. Arch Ophthalmol. 1980 Jan;98(1):82–85. doi: 10.1001/archopht.1980.01020030084004. [DOI] [PubMed] [Google Scholar]
  82. Tanaka S., Yamamoto H., Takeuchi S., Takeuchi T. Melanization in albino mice transformed by introducing cloned mouse tyrosinase gene. Development. 1990 Feb;108(2):223–227. doi: 10.1242/dev.108.2.223. [DOI] [PubMed] [Google Scholar]
  83. Tapper D., Langer R., Bellows A. R., Folkman J. Angiogenesis capacity as a diagnostic marker for human eye tumors. Surgery. 1979 Jul;86(1):36–40. [PubMed] [Google Scholar]
  84. Vinores S. A., Küchle M., Mahlow J., Chiu C., Green W. R., Campochiaro P. A. Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor. Am J Pathol. 1995 Nov;147(5):1289–1297. [PMC free article] [PubMed] [Google Scholar]
  85. Vit V. V. Prognosticheskoe znachenie morfologicheskikh priznakov immunnogo otveta pri uveal'nykh melanoblastomakh razlichnogo kletochnogo tipa. Arkh Patol. 1983;45(7):25–30. [PubMed] [Google Scholar]
  86. Weidner N., Carroll P. R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993 Aug;143(2):401–409. [PMC free article] [PubMed] [Google Scholar]
  87. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E. N., Moore D. H., Meli S., Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992 Dec 16;84(24):1875–1887. doi: 10.1093/jnci/84.24.1875. [DOI] [PubMed] [Google Scholar]
  88. Zakka K. A., Foos R. Y., Sulit H. Metastatic tapioca iris melanoma. Br J Ophthalmol. 1979 Nov;63(11):744–749. doi: 10.1136/bjo.63.11.744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Zhang Y., Deng Y., Luther T., Müller M., Ziegler R., Waldherr R., Stern D. M., Nawroth P. P. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994 Sep;94(3):1320–1327. doi: 10.1172/JCI117451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Zimmerman L. E., McLean I. W. Montgomery Lecture, 1975. Changing concepts of the prognosis and management of small malignant melanomas of the choroid. Trans Ophthalmol Soc U K. 1975;95(4):487–494. [PubMed] [Google Scholar]
  91. de la Cruz P. O., Jr, Specht C. S., McLean I. W. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990 Jan 1;65(1):112–115. doi: 10.1002/1097-0142(19900101)65:1<112::aid-cncr2820650123>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  92. ten Berge P. J., Danen E. H., van Muijen G. N., Jager M. J., Ruiter D. J. Integrin expression in uveal melanoma differs from cutaneous melanoma. Invest Ophthalmol Vis Sci. 1993 Dec;34(13):3635–3640. [PubMed] [Google Scholar]

Articles from Transactions of the American Ophthalmological Society are provided here courtesy of American Ophthalmological Society

RESOURCES